EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 168 filers reported holding EAGLE PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $264,096 | +4.8% | 9,309 | +77.3% | 0.00% | -50.0% |
| Q2 2020 | $252,000 | -33.0% | 5,251 | -16.0% | 0.00% | -33.3% |
| Q4 2019 | $376,000 | -78.4% | 6,250 | -79.7% | 0.00% | -75.0% |
| Q3 2019 | $1,739,000 | -19.8% | 30,733 | -21.0% | 0.01% | -14.3% |
| Q2 2019 | $2,167,000 | +10.7% | 38,918 | +0.4% | 0.01% | +7.7% |
| Q1 2019 | $1,957,000 | +30.6% | 38,768 | +4.2% | 0.01% | +30.0% |
| Q4 2018 | $1,499,000 | -46.3% | 37,193 | -7.7% | 0.01% | -37.5% |
| Q3 2018 | $2,794,000 | -7.7% | 40,293 | +0.8% | 0.02% | -5.9% |
| Q2 2018 | $3,026,000 | +23.7% | 39,993 | -13.9% | 0.02% | +13.3% |
| Q1 2018 | $2,446,000 | +30.7% | 46,425 | +32.5% | 0.02% | +36.4% |
| Q4 2017 | $1,871,000 | +40.7% | 35,025 | +57.1% | 0.01% | +37.5% |
| Q3 2017 | $1,330,000 | – | 22,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Euclidean Technologies Management, LLC | 72,263 | $2,112,247 | 2.01% |
| Krensavage Asset Management, LLC | 114,825 | $3,356 | 1.04% |
| Smith, Graham & Co., Investment Advisors, LP | 231,222 | $6,758,619 | 0.83% |
| TANG CAPITAL MANAGEMENT LLC | 118,857 | $3,474,190 | 0.50% |
| Capital Impact Advisors, LLC | 12,704 | $371,338 | 0.36% |
| BRANDES INVESTMENT PARTNERS, LP | 416,177 | $12,164,854 | 0.34% |
| Watershed Asset Management, L.L.C. | 9,148 | $267,396 | 0.34% |
| Jackson Creek Investment Advisors LLC | 25,171 | $736 | 0.33% |
| SummerHaven Investment Management, LLC | 17,608 | $514,682 | 0.31% |
| Campbell & CO Investment Adviser LLC | 22,547 | $659,049 | 0.16% |